UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2022

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-37471		30-0784346
(State or other jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)
· /	· · · · ,	03100	
25	5 State Street, 9th Floor	02109	
	Boston, MA		
(Add	ress of principal executive offices)	(Zip Code)	
	Registrant's telephone number, including a	rea code: 857-246-8998	
	N/A		
	(Former name or former address, if chan	ged since last report.)	
Check the appropriate box below if the Form 8-K filing is intended to simulta	neously satisfy the filing obligation of the registra	it under any of the following provisions:	
	· • • • • • • • • • • • • • • • • • • •		
□ Written communications pursuant to Rule 425 under the Securi	ties Act (1/ CFR 230.425)		
□ Soliciting material pursuant to Rule 14a-12 under the Exchange	Act (17 CFR 240.14a-12)		
□ Pre-commencement communications pursuant to Rule 14d-2(b)	under the Exchange Act (17 CFR 240.14d-2(b))		
□ Pre-commencement communications pursuant to Rule 13e-4(c)	under the Exchange Act (17 CFR 240.13e-4(c))		
Securities registered pursuant to Section 12(b) of the Act:			
Title of each class	Trading Symbol	s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	PIRS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On March 1, 2022, Pieris Pharmaceuticals, Inc. (the "Company") issued a press release announcing certain financial results for the fiscal year ended December 31, 2021. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

Furnished hereto as Exhibit 99.2 is the March 2022 Investor Presentation of the Company.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.2 furnished hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

- 99.1 Press Release, dated March 1, 2022.
- 99.2 Investor Presentation, dated March 2022.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

/s/ Tom Bures
Tom Bures
Chief Financial Officer

Dated: March 1, 2022

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST

- Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year Dosed first patient in phase 2 gastric study of cinrebafusp alfa; HER2-low arm data expected this year and HER2-high arm data expected in 2023 Dosed first patient in phase 1/2 solid tumor study of PRS-344/S095012 PRS-220 phase 1 initiation on track for this year Year-end cash and cash equivalents totaled \$117.8 million

BOSTON, MA, March 1, 2022 - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin[®] technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the fiscal year ended December 31, 2021 and provided an update on the Company's recent and anticipated future developments. "Last year was one of steady execution as we laid the groundwork for 2022, which we believe promises to be the most important catalyst year in the Company's history, including key efficacy data for cinrebafusp alfa and PRS-060/AZD1402. We announced a collaboration with R&D leader Genentech, reported data from several clinical and preclinical programs, and initiated multiple clinical trials. Later this year, we expect to report topline data from the phase 2a trial of PRS-060/AZD1402, we currently have two bispecific immuno-oncology programs in clinical development and plan on initiating clinical development for our proprietary inhaled-delivery indiced for PIeris. "Through these initiatives, we have advanced our pipeline assets while strengthening our balance sheet through partnerships, grant funding, and focused utilization of our ATM facility, all with the focus of driving toward our key inflection point."

- PRS-060/AZD1402 and AstraZeneca Collaboration: Enrollment of part 2a (efficacy of 1 mg and 3 mg cohorts) and part 1b (safety of 10 mg cohort) has begun following successful completion of the sponsor safety review of part 1a (safety of 1 mg and 3 mg cohorts) of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD1402. PRS-060/AZD1402 is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Pieris and AstraZeneca expect to announce topline data from the phase 2a study this year, although the companies are actively evaluating the feasibility of study timelines in the current geopolitical environment and will update guidance in the orderly course of business, if needed. Upon completion of the study, which is being sponsored and funded by AstraZeneca, Pieris and future option to co-commercialize PRS-060/AZD1402 in the United States. **Cinrebafusp Alfa (PRS-343)**: In January 2022, the first patient was dosed in the phase 2 study of cinrebafusp alfa, a 4-1BB/HER2 Anticalin-based bispecific for the treatment of HER2-expersing gastric cancer. The two-arm, multicenter, open-label phase 2 study is evaluating the efficacy, safety, and tolerability of cinrebafusp alfa in combination with HER2-high gastric cancer and in combination with tucatinib in patients with HER2-low gastric cancer. Pieris plans to report data from the HER2-low arm this year. Separately, the Company plans to disclose data from the HER2-high arm in 2023.
- PRS-344/S095012 and Servier Collaboration: The first patient was dosed in November 2021 in the phase 1/2 study of PRS-344/S095012, a 4-1BB/PD-L1 Anticalin-based bispecific for

treatment of solid tumors, triggering an undisclosed milestone payment to Pieris. Pieris holds exclusive commercialization rights for PRS-344/S095012 in the United States and will receive royalties on any ex-U.S. sales for this program. Additionally, Servier is continuing development of PRS-352, an undisclosed Anticalin-based bispecific beyond 4-1BB. PRS-220: Pieris remains on track to begin a phase 1 trial this year for PRS-220, a proprietary inhaled Anticalin protein targeting connective tissue growth factor for the treatment of IPF. Year End Financial Update:

<u>Cash Position</u> – Cash and cash equivalents totaled \$117.8 million for the year ended December 31, 2021, compared to a cash and cash equivalents balance of \$70.4 million for the year ended December 31, 2020. The increase since December 2020 is due to cash received from new and existing collaboration agreements, including milestone achievements. In addition, during 2021, the ATM program was utilized to raise a total of \$38.5M in net proceeds at an average price of \$4.85 per share. These increases were partially offset by cash used to fund operations in 2021.

<u>R&D Expense</u> - R&D expenses were \$66.7 million for the year ended December 31, 2021, compared to \$46.5 million for the year ended December 31, 2020. The increase reflects higher spending on preclinical and manufacturing activities for PRS-220, an increase in manufacturing costs across multiple immuno-oncology programs, higher clinical costs on cinrebafusp alfa and higher employee related costs. These increases were partially offset by lower manufacturing costs on PRS-060, which were fully reimbursed.

<u>G&A Expense</u> - G&A expenses were \$16.5 million for the year ended December 31, 2021, compared to \$16.7 million for the year ended December 31, 2020. Total G&A spending was consistent year-over-year as higher fixed and variable compensation and higher insurance costs in 2021 were offset by lower legal, accounting, and project management costs, along with lower one-time office and building equipment costs related to the move to the new R&D facility in Hallbergmoos, Germany in the prior year.

<u>Other Income</u> - For the year ended December 31, 2021, \$3.7 million of other income was recorded for PRS-220 program costs that qualified for reimbursement under the Bavarian grant that was announced in June 2021. The Bavarian government reimburses these qualifying program costs as incurred over the PRS-220 development period.

Net Loss - Net loss was \$45.7 million or \$(0.71) per share for the year ended December 31, 2021, compared to a net loss of \$37.2 million or \$(0.68) per share for the year ended December 31, 2020.

Conference Call: Pieris management will host a conference call beginning at 8:00 AM EST on Tuesday, March 1, 2022, to discuss the full-year financial results and provide a corporate update. Individuals can join the call by dialing +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International). Alternatively, a listen-only audio webcast of the call can be accessed <u>here</u>.

For those unable to participate in the conference call or listen to the webcast, a replay will be available on the Investors section of the Company's website, www.pieris.com.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit <u>www.pieris.com</u>.

Forward-looking Statements:

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements.

Such forward-looking statements include, among other things, the potential for Pieris' development programs such as PRS-060/AZD1402, cinrebafusp alfa, PRS-344/S095012 and PRS-220 to address our core focus areas such as respiratory diseases and immuno-oncology; the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data; making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, cinrebafusp alfa, PRS-344/S095012 and PRS-220; the therapeutic potential of our Anticalin platform; our continued progress in the areas of co-stim bispecifics and inhaled therapeutics; and the advancement of our developmental programs generally. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; competition in the industry in which we operate; delays or disruptions due to COVID-19 or geo-political issues, including the conflict in Ukraine; and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set offic in the reports and other documents we file with the Securities and Exchange Commission available at www.sec.gov, including, with

Investor Relations Contact:

Pieris Pharmaceuticals, Inc. Maria Kelman Executive Director, Investor Relations +1 857 362 9635 kelman@pieris.com

PIERIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

	December	31,
	2021	2020
Assets:		
Cash and cash equivalents	\$ 117,764	\$ 70,436
Short term investments	_	_
Accounts receivable	3,313	1,706
Prepaid expenses and other current assets	6,548	3,579
Total current assets	127,625	75,721
Property and equipment, net	19,122	22,046
Operating lease right-of-use assets	3,909	3,934
Other non-current assets	2,904	3,309
Total Assets	\$ 153,560	\$ 105,010
Liabilities and stockholders' equity:		
Accounts payable	\$ 8,609	\$ 1,787
Accrued expenses	16,836	7,731
Deferred revenue, current portion	25,116	12,627
Total current liabilities	50,561	22,145
Deferred revenue, net of current portion	38,403	35,900
Operating lease liabilities	13,841	15,932
Other long-term liabilities	—	6
Total Liabilities	102,805	73,983
Total stockholders' equity	50,755	31,027
Total liabilities and stockholders' equity	\$ 153,560	\$ 105,010

PIERIS PHARMACEUTICALS, INC CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data)

	Twelve Months Ended December 31,	
	2021	2020
Revenues	\$ 31,418	\$ 29,323
Operating expenses		
Research and development	66,656	46,531
General and administrative	16,593	16,713
Total operating expenses	83,249	63,244
Loss from operations	(51,831)	(33,921)
Interest income	4	511
Grant income	3,685	_
Other income (expense), net	2,404	(3,656)
Loss before income taxes	(45,738)	(37,066)
Provision for income tax		164
Net loss	\$ (45,738)	\$ (37,230)
Basic and diluted net loss per share	\$ (0.71)	\$ (0.68)
Basic and diluted weighted average shares outstanding	64,547	54,481







Forward-Looking Statements

This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the fiming for initiation of clinical triais of PRS-220, whether PRS-220 will provide a clinical benefit in the treatment of IPF and PASC-related fibrosis, whether the combination of cinrebalusp alfa with other threnzpies could address a high medical need in HER2 gastric cancer patients who do not respond to traditional HER2-targeted therapies; whether the replicated therapies; whether the replicated that is under therapies cancer, the expected timing and potential automes of the reporting by the Company of key clinical data from tilts programs, references to novel technologies and methods and our business and product development plans, including the Company's calar sources, the advancement of our proprietary and c-development programs including PRS-600/AD1402, cinrebafusp alfa. PRS-344, and PRS-352, and the expected timing of the initiation of the next stage of cinrebafusp alfa's development in a product development plans, including the Company's calar sources, the advancement of our proprietary and c-development plans, including PRS-600/AD1402, cinrebafusp alfa's development in gastric cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent tuncertainties associated with developing mer yordcus to rechonologies and operating as a development stage company, our ability to areise to address to the U.S. Food and Drug Administration; competition in the industry in which we operate; delays or disruptions due to QVID-19; and market conditions. These forward-looking statements are made as of th



Our Formula for Success

We combine leading protein engineering capabilities and deep insights into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients.



-pieris-

Executive Summary

via Efficient Biology	 Protein therapeutics that exploit biology validated by mAbs yet are engineered for focused activity at disease locus Improved activity, reduced side effects, increased convenience
Two Focus Areas	 Oral inhaled antagonists for respiratory disease Locally activated immuno-oncology bispecifics 2 POC readouts this year; several follow-on candidates
Supportive Partnerships	 ~\$200M since 2017 in upfronts, milestones and equity investments Several co-developed and out-licensed programs Clinical supply for combination studies and development expertise

Anticalin® Proteins as Therapeutic Modalities

A Novel Therapeutic Class with Favorable Drug-Like Properties

- Human Derived from lipocalins (human extracellular binding proteins)
- Small Monomeric, monovalent, small size (~18 kDa vs. ~150kDa mAbs)
- Stable Inhalable delivery
- Simple Bi/multispecific constructs
- Proprietary Broad IP position on platform and derived products


Translational Science Expertise to Deploy Platform in Meaningful Way

- Immunology expertise underpins IO and respiratory focus
- A leader in 4-1BB and costim biology
- Patient phenotyping efforts for improved stratification and novel intervention points in, e.g., asthma



-pieris-

Two-fold Focus of Anticalin Platform Deployment




Our Pipeline


CANDIDATE	TARGETS	INDICATION	PARTNER	OUR COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	Phase 1	Phase 2
PRS-060/AZD1402	IL4-Rα	Asthma	AstraZeneca	Worldwide Gross Margin Option				
PRS-220	CTGF	IPF, PASC-PF	n/a	Worldwide				
AstraZeneca Programs*	n.d.	n.d.	AstraZeneca	Worldwide Gross Margin Options				
Genentech Programs*	n.d.	n.d.	Genentech	Royalties				
*3 respiratory programs in col	laboration with A	straZeneca, 2 of w	hich carry co-deve	lopment and co-commercialization o	ptions for Pieris			
*Collaboration includes 1 resp	iratory program	and 1 ophthalmolo	gy program					
			571 5					
IMMUNO-ONCOLOGY								
CANDIDATE	TARGETS	INDICATION	PARTNER	OUR COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	Phase 1	Phase 2
		HER2-High GC**						
Cinrebafusp Alfa (PRS-343)	4-1BB/HER2	HER2-Low GC**	n/a	Worldwide		4 4.		
PRS-344/S095012	4-1BB/PD-L1	n.d.	* Senvien	US Rights; ex-US Royalties				
PRS-352	n.d.	n.d.	* SERVICE	Royalties				
PRS-342/BOS-342	4-1BB/GPC3	n.d.	BOSTON	Royalties				
Seagen Programs [‡]	Co-stim Agonist	n.d.	OSeagen	US Co-Promotion Option; Royalties				
[‡] 3 bispecific programs in colla	boration with Se	agen, with Pieris re	itaining a US co-pr	omotion option for the second progr				

Validating Partnerships with Leading Companies






PRS-060/AZD1402: Inhaled IL-4Rα Antagonist



10


-pieris-

PRS-060/AZD1402 Progressed into Efficacy Portion of Phase 2a




DPI Formulation of PRS-060/AZD1402 Passed Safety Review


31 moderate asthmatics controlled on Safety review performed of the following (compared to placebo): standard-of-care (medium dose ICS with LABA) asthma therapy were \checkmark Incidence of adverse events dosed twice daily over four weeks Changes in laboratory markers randomized across two dose levels ~ (immune biomarkers, clinical and placebo arm (1:1:1) chemistry, and hematology) Forced expiratory volume in 1 second Safety review successfully completed \checkmark (FEV1) for two different dose levels that will now be explored for efficacy in participants with asthma uncontrolled on medium dose ICS-LABA Pharmacokinetics \checkmark -pieris-12




Moderate-to-Severe Asthma Market Opportunity



Co-Development Options for PRS-060/AZD1402




PRS-220: Inhaled CTGF Antagonist




-pieris-

IPF: High Unmet Medical Need and Significant Commercial Opportunity



CTGF: Clinically Validated Intervention for IPF

- Connective tissue growth factor (CTGF), or CCN2, a protein localized in the extracellular matrix, is a driver of fibrotic remodeling as consequence of an aberrant wound healing process
- Over-expression of the protein in lung tissue is observed in patients suffering from IPF
- Competitor clinical data indicate inhibition of CTGF reduces the decline in lung function among patients with IPF
- Competitor compound requires highdose infusions to effectively target lungresident CTGF




CTGF affects multiple signaling pathways and processes important in pathophysiology. CTGF interacts with a variety of molecules, including cytokines and growth factors, receptors and matrix proteins. These interactions alter signa ransduction pathways, either positively or negatively, which results in changes in cellular resoneses.

(Lipson, Fibrogenesis & Tissue Repair, 201)

-pieris-

PRS-220: Inhaled Solution



Grant from Bavarian Government to Support Program Acceleration and Evaluation of Efficacy in PASC-PF



approximately 14 million euro grant from the Bavarian government for the research and development of PRS-220 for post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF)


Grant will:

- Allow Pieris to accelerate development of the program IND planned 2022
- Support clinical-readiness activities and initial clinical development for the program, including GLP tox studies, GMP manufacturing, and phase 1 clinical development

 Broaden scope of the program beyond the original IPF indication by including the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis

-pieris-

PRS-220 for PASC-PF



Cinrebafusp Alfa (PRS-343): Lead IO Asset


Candidate	Cinrebafusp alfa (PRS-343)	HER2-Targeting Antibody
Function/MoA	Tumor-targeted 4-1BB agonism and HER2 antagonism	
Indications	HER2-high and HER2-low gastric cancer	
Development	Phase 2	
Commercial Rights	Fully proprietary	4-1BB-Targeting Anticalin Proteins

Cinrebafusp Alfa Phase 1 Summary

- Acceptable profile observed at all doses tested with no dose-limiting toxicities
- Clinical benefit at active dose levels (≥ 2.5 mg/kg), including confirmed complete response and several confirmed partial responses
- Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients
- Durable anti-tumor activity in heavily pre-treated patient population, including "cold" tumors
- As lead IO program, cinrebafusp alfa provides key validation of 4-1BB franchise and follow-on programs, including PRS-344 and PRS-342

-pieris

Cinrebafusp Alfa Phase 1 Monotherapy Study



Phase 1 Monotherapy Treatment-related Adverse Events at Active Doses (≥ 2.5 mg/kg)

reatment-related Adverse Events (TRAEs occurring in > 1 patient; n = 53)	All Grades n (%)	Grade 1-2 n (%)	Grade 3-4 n (%)
Infusion-related reaction	13 (25%)	9 (17%)	4 (8%)
Nausea	7 (13%)	7 (13%)	
Chills	6 (11%)	6 (11%)	
Vomiting	6 (11%)	6 (11%)	
Dyspnea	4 (8%)	4 (8%)	
Fatigue	4 (8%)	4 (8%)	
Arthralgia	3 (6%)	2 (4%)	1 (2%)
Decreased appetite	3 (6%)	3 (6%)	
Non-cardiac chest pain	3 (6%)	3 (6%)	
Asthenia	2 (4%)	2 (4%)	
Diarrhea	2 (4%)	2 (4%)	
Dizziness	2 (4%)	2 (4%)	
Headache	2 (4%)	2 (4%)	
Paresthesia	2 (4%)	1 (2%)	1 (2%)
Pruritus	2 (4%)	2 (4%)	
Pyrexia	2 (4%)	2 (4%)	
Rash	2 (4%)	2 (4%)	

⁻pieris-

Jelae. Data cut-off: 25-Feb-21

Total	9	10	11	11b	Obi	11c	12b	13b	Cohort
	2.5 mg/kg, Q3W	5 mg/kg, Q3W	8 mg/kg, Q3W	8 mg/kg, Q2W	8 mg/kg, Q2W	8 mg/kg, QW	12 mg/kg, Q2W	18 mg/kg, Q2W	Best Response
42	5	7	4	7	4	5	2	8	Evaluable Patients
1	-	-	-	-	-	-	-	1	CR
4	-	-	-	3	-	-	-	1	PR
17	2	3	3	3	2	1		3	SD
12%	0%	0%	0%	43%	0%	0%	0%	25%	ORR
52%	40%	43%	75%	86%	50%	20%	0%	63%	DCR

26

Summary of Responses in Phase 1 Monotherapy Study

-pieris-


Summary of Responses in 4-1BB Bispecific Phase 1 Monotherapy Study

Cohort 13b		12b	11b	Obi	11c	9	10	11	
Best Response	18 mg/kg, Q2W	12 mg/kg, Q2W	8 mg/kg, Q2W	8 mg/Kg, Q2W	8 mg/kg, QW	2.5 mg/kg, Q3W	5 mg/kg, Q3W	8 mg/kg, Q3W	Total
Evaluable Patients	8	2	7	4	5	5	7	4	42
CR	1	-	-	-	-	-	-	-	1
PR	1	-	3	-	-	-	-	-	4
SD	3	-	3	2	1	2	3	3	17
ORR	25%	0%	43%	0%	0%	0%	0%	0%	12%
DCR	63%	0%	86%	50%	20%	40%	43%	75%	52%


-pieris-

Data cut-off: 25-Feb-21


Cinrebafusp Alfa Phase 1 Monotherapy Efficacy Data: Analysis of Patients Treated at Active Doses




Durable Responses with Cinrebafusp Alfa Among Heavily Pre-treated Population Overall Population




Cinrebafusp Alfa Shows Dose-dependent Activity Across Key Pharmacodynamic Parameters




Cinrebafusp Alfa Activates Adaptive and Innate Immunity in the Tumor







Single-Agent Activity in Both "Hot" and "Cold" Tumors



Signs of Preclinical and Clinical Activity in the HER2-Low Setting




Cinrebafusp Alfa Clinical Development Plan



Cinrebafusp Alfa Opportunity in HER2-High &

PRS-344/S095012: Meaningfully Building on Localized MoA of Cinrebafusp Alfa





PRS-344 Drives Strong Anti-tumor Activity in Anti-PD-L1 mAbresistant Mouse Model


Financial Overview (as of 12/31/21)







PRS-060 Phase 1 Multiple Ascending Dose Trial




Phase 1b Interim Results: Favorable Safety Profile

- All doses of AZD1402/PRS-060 tested in the study were well tolerated
- No treatment-related serious AEs were observed

System organ class AE Preferred Terms ^b	Placebo (N = 12) n (%) m	AZD1402/PRS-060° (N = 30) n (%) m	Overall (N = 42) n (%) m	
Gastrointestinal disorders	4 (33.3) 4	13 (43.4) 14	17 (40.5) 18	
Dry mouth	1 (8.3) 1	2 (6.7) 2	3 (7.1) 3	
Nausea	1 (8.3) 1	3 (10.0) 3	4 (9.5) 4	
Infections and infestations	1 (8.3) 1	7 (23.3) 8	8 (19.0) 9	
Upper respiratory tract infection	1 (8.3) 1	3 (10.0) 4	4 (9.5) 5	
Nervous system disorders	5 (41.7) 9	13 (43.4) 18	18 (42.9) 27	
Headache	3 (25.0) 6	5 (16.7) 7	8 (19.0) 13	
Presyncope	0	4 (13.3) 6	4 (9.5) 6	
Respiratory, thoracic and mediastinal disorders	6 (50.0) 6	14 (46.7) 15	20 (47.6) 21	
Cough	1 (8.3) 1	4 (13.3) 4	5 (11.9) 5	
Rhinorrhoea	2 (16.7) 2	1 (3.3) 1	3 (7.1) 3	
Wheezing	2 (16.7) 2	4 (13.3) 5	6 (14.3) 7	

41


-pieris-



Phase 1b Interim Results: Robust FeNO Reduction

Phase 1b Interim Results: Pharmacological Versatility

pSTAT6 levels over time following inhalation of PRS-060



No systemic target engagement and minimal systemic exposure was observed at the 2 mg dose, suggesting that local target engagement by the drug is sufficient to reduce airway inflammation

Pharmacological versatility, given lowdose FeNO reduction with no observed systemic activity (pSTAT6) versus high-dose FeNO reduction with systemic activity


43




Phase 1 Monotherapy Baseline Characteristics (N = 78)

Characteristic	n (%)	Primary Cancer Type	n (%)	
Age, Median (range)	63 (24–92)	Gastroesophageal	34 (44%)	
Gender		Gastroesophagear		
F	46 (59%)	Breast	16 (21%)	
M 32 (41%)		Brodot	(=: ,;;)	
ECOG PS		Colorectal	12 (15%)	
0	19 (24%)			
1	59 (76%)	Gynecological	9 (12%)	
Prior Therapy Lines			2 (3%)	
1 11 (14%)		Bladder		
2 10 (13%)		Pancreatic	1 (1%)	
3 16 (21%)		Failcreatic		
4 12 (15%)		Other – Cancer	2 (3%)	
5+	29 (37%)	of Unknown Origin	2 (3%)	
Median # of anti-HER2 Tx		Other - Salivary Duct	1 (1%)	
Breast 6				
Gastric	2	Melanoma	1 (1%)	
			Data cut-off: 25-Feb-	
ieris-				

Cinrebafusp Alfa Phase 1 Monotherapy Efficacy Data: Analysis of Patients Treated at Active Doses







Case Study: PR in Cancer of Unknown Primary Patient Profile, Treatment History and Treatment Outcome

ial diagnosis October 2019		n Radical Prostatectomy ation oplatin + gemcitabine		s4-1BB Serum Fold change to baseline	\$\$\$\$\$\$\$\$\$
	1		Lesion Si		Timepoint (days)
Lesions	Lesion Site	Pre-treatment	Post-treatment		
			Cycle 2	Cycle 4	Cycle 6
Target 1	Lung, right lower lobe mass	25	13	0	0
	Total	25	13	0	0
	% Change from Baseline		-48%	-100%	-100%
			Not assessed		Present
Non-target 1	Lung, bilateral pulmonary masses	Present	Not assessed	Present	Present
Non-target 1 Non-target 2		Present	Not assessed	Present	Present

Case Study: SD in Colorectal Cancer

Patient Profile,	i reatment r	listory and	Treatment	Outcome	

itial diagnosis Jan 2009 Fold Itage 4 Colorectal Adenocarcinoma Folf ancer Folf Ancer Stable; KRAS, NRAS, BRAF wt Iras ISI stable; KRAS, NRAS, BRAF wt Inve antii		or lines of therapy, includir i x + Avastin + bevacizumab uzumab/pertuzumab tigational agent (immune ody conjugate (ISAC) with uzumab	stimulator		Store of the store
		_	Lesion S	Size (mm)	,
Lesions	Lesion Site	Pre-treatment	Post-treatment		
			Cycle 2	Cycle 4	Cycle 6*
Target 1	Lung, right upper lobe pulmonary nodule	10	8	8	
Target 2	Lung, right lower lobe pulmonary nodule	12	11	11	
	Total	22	19	19	-
	% Change from Baseline		-14%	-14%	-
	Lung, multiple pulmonary	Present	Present	Present	-
Non-target 1	nodules	1 rooont			




Soluble 4-1BB (s4-1BB): Blood-based Biomarker of Cinrebafusp Alfa Engagement

- s4-1BB is an alternatively spliced form of 4-1BB receptor lacking the transmembrane encoding exon (Setareh et al., 1995; Shao et al., 2008)
- s4-1BB is **released by leukocytes in an activation-dependent manner** (Michel et al., 2000; Salih et al., 2001; Schwarz et al., 1996)
- s4-1BB is **produced with a slightly delayed kinetic to pathway activation**. Hypothesized role as a negative regulator, keeping 4-1BB-mediated co-stimulation in check

s4-1BB utility as a pathway specific biomarker provides ability to track cinrebafusp target engagement and activity using serum samples


51

-pieris-




Scientific Rationale for Combining Cinrebafusp Alfa & SoC






Scientific Rationale for Combining Cinrebafusp Alfa & Tucatinib



Cinrebafusp Alfa and Tucatinib Combination Enhances T cell Activation



255 State Street Boston, MA 02109 USA Zeppelinstraße 3 85399 Hallbergmoos Germany



Nasdaq: PIRS

